ArticleJournal of clinical and diagnostic research : JCDR2017
Breast Biomarkers-Comparison on Whole Section and Tissue Microarray Section.
Article in Journal of clinical and diagnostic research : JCDR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 17 citations in OpenAlex.
- Article
- Article
- Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer.Frontiers in medicine · 2019Article
- Comparison of TMA Technique and Routine Whole Slide Analysis in Evaluation of Proliferative Markers Expression in Laryngeal Squamous Cell Cancer.In vivo (Athens, Greece)Article
- Unlocking breast cancer in Brazilian public health system: Using tissue microarray for accurate immunohistochemical evaluation with limitations in subtyping.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEstrogen Receptor (ER), Progesterone Receptor (PR) and Her2/neu are routinely studied markers for breast carcinoma. Analysis of these biomarkers is traditionally done by Immunohistochemistry (IHC) on whole sections. These markers can also be studied on Tissue Microarray (TMA) sections. Tissue microarray is a technique where core samples from different paraffin blocks are arrayed on a single recipient block which can then be cut to yield a single section with multiple cores in it.
aimTo compare ER, PR and Her2/neu on TMA sections with whole sections and to determine the concordance of results between the two methods. MATERIALS AND
methodsA TMA block was constructed by punching out 2 mm cores from appropriately marked paraffin blocks of 53 breast carcinoma cases and embedding them in the recipient block. Immunostaining of TMA sections and whole sections were performed for ER, PR and Her2/neu and the results were compared. Statistical analysis was done using chi square test/Fisher-Exact test. Kappa co-efficient, Jaccard Index and G-Index were computed.
resultsInfiltrating Ductal Carcinoma-No Special Type (IDC-NST) was the predominant type of carcinoma and most of the tumours were of Grade II and III. Majority, 38/53 (71.7%) were ER/PR positive and Her2 negative and 9/53 (17%) cases were triple negative. Good concordance between whole sections and TMA sections were noted with kappa value for ER, PR and Her2/neu being 0.671, 0.754, 1.000 respectively which was statistically significant.
conclusionImmunostaining for ER, PR and Her2/neu done on TMA section using single 2 mm core were comparable with conventional whole section scores. Thus, TMA is a reliable method for evaluating these biomarkers with the advantage of being time and cost effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.